Abstract
Background Studies have shown that there is a high prevalence of depression in cancer patients. Women with breast cancer may have an even higher risk of depression particularly in a postmenopausal or estrogen deficiency state. A small number of randomized controlled trials have examined the efficacy of antidepressants compared to that of a placebo in cancer patients, but some results have been difficult to interpret due to a heterogeneous patient group. In the current investigation, we screened newly diagnosed early stage breast cancer patients for depressive symptoms prior to the initiation of adjuvant therapy and investigated whether the oral antidepressant fluoxetine affected depressive symptoms, completion of adjuvant treatment, and quality of life. Methods Patients with newly diagnosed early stage breast cancer were screened for depressive symptoms prior to the initiation of adjuvant therapy. Patients with depressive symptoms were randomized to a daily oral fluoxetine or a placebo. Patients were then followed for 6 months and evaluated for quality of life, completion of adjuvant treatment, and depressive symptoms. Results A high percentage of patients with newly diagnosed early stage breast cancer were found to have depressive symptoms prior to the initiation of adjuvant therapy. The use of fluoxetine for 6 months resulted in an improvement in quality of life, a higher completion of adjuvant treatment (chemotherapy, hormonal therapy, chemotherapy plus hormonal therapy), and a reduction in depressive symptoms compared to patients who received placebo. Conclusions An antidepressant should be considered for early stage breast cancer patients with depressive symptoms who are receiving adjuvant treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fisch MJ, Loehrer PJ, Kristeller J et al (2003) Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the hoosier oncology group. J Clin Oncol 21:1937–1943
Coyne JC, Palmer SC, Shapiro PJ et al (2004) Distress, psychiatric morbidity, and prescriptions for psychotropic medication in a breast cancer waiting room sample. J Gen Hosp Psychiatry 26:121–128
Pirl WF, Roth AJ (1999) Diagnosis and treatment of depression in cancer patients. Oncology 13(9):1293–1301
Roth AJ, Winnell J (2004) Depression in cancer patients. Oncology 18(12):1554–1560
Pezzella G, Moslinger-Gehmayr R, Contu A (2001) Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat 70:1–10
Passik SD, Dugan W, McDonald MV et al (1998) Oncologists’ recognition of depression in their patients with cancer. J Clin Oncol 16:1594–1600
Mann JJ (2005) The medical management of depression. N Engl J Med 353:1819–34
Costa D, Mogos I, Toma T (1985) Efficacy and safety of Mianserin in the treatment of depression in women with cancer. Acta Psychiatr Scand 72:499–503
Foley KM, Gelband H (eds) (2001) Improving palliative care for cancer: summary and recommendations. National Academy Press, Washington
Somerset W, Stout SC, Miller AH et al (2004) Breast cancer and depression. Oncology 18(6):1021–1034
Morrow GR, Hickok JT, Roscoe JA et al (2003) Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 21:4635–4641
Roscoe JA, Morrow GR, Hickok JT et al (2005) Effect of paroxetine hydrochloride (Paxil®) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 89:243–249
Burgess C, Cornelius C, Love S et al (2005) Depression and anxiety in women with early breast cancer: five year observational cohort study. Br Med J 330(7493):702
Monti DA, Mago R, Kunkel EJ (2005) Depression, cognition, and anxiety among postmenopausal women with breast cancer. Psychiatr Serv 56(11):1353–1355
Prieto JM, Atala J, Blanch J et al (2005) Role of depression as a predictor of mortality among cancer patients after stem-cell transplantation. J Clin Oncol 23:6063–6071
Thompson DS (2000) Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology. Psychosomatics 41(4):356–359
Wong-Kim EC, Bloom JR (2005) Depression experienced by young women newly diagnosed with breast cancer. Psychooncology 14:564–573
Colleoni M, Mandala M, Peruzzotti G et al (2000) Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet 356:1326–1327
Razavi D, Allilaire J, Smith M et al (1996) The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr Scand 94:205–210
van Heeringen K, Zivkov M (1996) Pharmacological treatment of depression in cancer patients: a placebo-controlled study of mianserin. Br J Psychiatry 169:440–443
Eija K, Tiina T, Pertti NJ (1996) Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain 64:293–302
Purohit DR, Navlakha PL, Modi RS et al (1978) The role of antidepressants in hospitalized cancer patients: a pilot study. J Assoc Physicians India 26:245–248
Musselman DL, Lawson DH, Gumnick JF et al (2001) Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344:961–966
Peretti S, Judge R, Hindmarch I (2000) Safety and tolerability considerations tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 403:17–25
Cella DF, Tulsky DS, Gray G et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11: 570–579
Passik SD, Kirsh K, Donaghy KB et al (2001) An attempt to employ the Zung self-rating depression scale as a “lab test” to trigger follow-up in ambulatory oncology clinic: Criterion validity and detection. J Pain Symptom Manage 21:273–281
Acknowledgement
The Reich Family Endowment provided financial support for this investigation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Navari, R.M., Brenner, M.C. & Wilson, M.N. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat 112, 197–201 (2008). https://doi.org/10.1007/s10549-007-9841-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-007-9841-z